MAZE Maze Therapeutics, Inc.
Price Chart
Executive Summary
CEO Jason Coloma and President/CMO Harold Bernstein sold a combined $441K in open-market shares within days of Maze Therapeutics reporting Q1 2026 earnings and completing a $150M offering. The $441K total ($393K from Bernstein, $47K from Coloma) is 0.03% of the $1.4B market cap — well below any material threshold. Bernstein's sale coincided with a same-day exercise of 15,000 options at $10.42, indicating a standard cashless exercise/cover transaction rather than a discretionary bearish bet. The cluster is routine and driven by post-earnings window opening, not informed selling.
Key Financial Metrics
Actionable Insight
This cluster is structurally a post-earnings, post-offering, option-exercise-triggered sale — not a signal of deteriorating fundamentals. The 0.03% of market cap is immaterial. C-suite selling of this magnitude at a pre-revenue biotech is routine window-driven diversification. The stronger signal is the $150M raise and extended runway; monitor the MZE829 pivotal trial readout and MZE782 Phase 2 starts for true catalysts.
Key Facts
- CEO Coloma sold 1,822 shares at $26.00 for $47,372 on May 15
- CMO Bernstein sold 15,000 shares at $26.22 for $393,354 on May 14
- Bernstein simultaneously exercised 30,000 total options (15,000 at $10.42 and 15,000 in a separate non-cash exercise), covering tax obligations
- Total cluster value of $441K represents 0.03% of Maze's $1.4B market cap
- Insider cluster came 6 days after Maze reported Q1 2026 earnings with a narrower net loss of $24.2M vs $32.8M YoY
- Maze completed a $150M registered offering in April 2026 extending cash runway into 2029
Financial Impact
$441K in open-market sales; 0.03% of market cap - trivial
Risk Factors
- Pre-revenue biotech with reliance on clinical pipeline milestones for equity valuation
- All past MAZE reports show negative T+20 average alpha (-21.9%), suggesting structural downward drift in this name independent of filing content
- Post-offering dilution overhang from $150M April raise still being digested
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MAZE-1779138486836 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
Insider Cluster
| $25.40 $24.27 | ▲ +4.45% | ▲ +1.85% | $23.93 (+5.79%) |
|
May 22, 2026
18d ago
|
8-K
| $26.35 $26.05 | ▼ −1.14% | ▼ −1.15% | $23.93 (−9.18%) |
|
May 18, 2026
22d ago
|
Insider Cluster
| $24.46 $25.03 | ▲ +2.33% | ▲ +1.29% | $23.93 (−2.17%) |
|
May 12, 2026
28d ago
|
8-K
| $26.96 $26.96 | · 0.00% | ▲ +0.00% | $23.93 (−11.24%) |
|
May 12, 2026
28d ago
|
Press Release
| $26.96 $26.96 | · 0.00% | ▲ +0.00% | $23.93 (−11.24%) |
|
Apr 22, 2026
6w ago
|
424B5
| $26.01 $25.81 | ▼ −0.77% | ▼ −1.55% | $23.93 (−8.00%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $31.73 $31.71 | ▼ −0.06% | ▲ +1.71% | $23.93 (−24.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access